The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Neoadjuvant chemotherapy with or without preoperative irradiation in stage IIIA/N2 non-small cell lung cancer (NSCLC): A randomized phase III trial by the Swiss Group for Clinical Cancer Research (SAKK trial 16/00).
Miklos Pless
Consultant or Advisory Role - Sanofi
Roger Stupp
No relevant relationships to disclose
Hans-Beat Ris
No relevant relationships to disclose
Rolf A. Stahel
No relevant relationships to disclose
Walter Weder
No relevant relationships to disclose
Sandra Thierstein
No relevant relationships to disclose
Alexandros Xyrafas
No relevant relationships to disclose
Martin Frueh
No relevant relationships to disclose
Richard Cathomas
Consultant or Advisory Role - Sanofi
Research Funding - Sanofi
Alfred Zippelius
No relevant relationships to disclose
Arnaud Roth
No relevant relationships to disclose
Milorad Bijelovic
No relevant relationships to disclose
Adrian Ochsenbein
No relevant relationships to disclose
Urs R. Meier
No relevant relationships to disclose
Christoph Mamot
No relevant relationships to disclose
Daniel Rauch
No relevant relationships to disclose
Oliver Gautschi
No relevant relationships to disclose
Daniel C. Betticher
Consultant or Advisory Role - Sanofi
Rene-Olivier Mirimanoff
No relevant relationships to disclose
Solange Peters
No relevant relationships to disclose